CGI Pharmaceuticals

company

About

CGI Pharmaceuticals, Inc. is a private, development-stage pharmaceutical company.

  • 11 - 50

Details

Last Funding Type
Series C
Last Funding Money Raised
$22.30M
Industries
Biotechnology,Genetics,Health Care,Pharmaceutical
Founded date
Jan 1, 1998
Number Of Employee
11 - 50
Operating Status
Active

Founded out of Yale University, CGI (formerly Cellular Genomics Inc.) began operations in 2000. CGI, in conjunction with several biotech and pharmaceutical partners (Pfizer, Serono, Lilly, Affymetrix, and Schering AG), utilized a unique chemical-genetics approach known as “ASKA” (Analog Sensitive Kinase Alleles) to understand kinase function.

CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, as well as drug metabolism/pharmacokinetics (DMPK) expertise.

Utilizing its comprehensive chemistry capabilities, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000 compounds (all compounds designed and synthesized by CGI). To date, CGI has been awarded 8 U.S. patents covering its novel collection of kinase inhibitors. Moreover, all three of CGI’s drug discovery and development programs are based on hits obtained from CGI’s library.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$22.30M
CGI Pharmaceuticals has raised a total of $22.30M in funding over 2 rounds. Their latest funding was raised on Jan 21, 2004 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 21, 2004 Series C $22.30M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
CGI Pharmaceuticals is funded by 1 investors. Coastview Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Coastview Capital Series C